Our Mission

Exelgen Ltd integrates leading edge technology and innovative science to deliver consistently superior research products and services to the biotechnology, pharmaceutical and other life science enterprises. We partner with our customers to accelerate and improve the creation of life-enhancing products on their behalf.

Background

Exelgen Ltd, based in Bude, Cornwall, UK, is a wholly owned subsidiary of Commonwealth Biotechnologies Inc., of Richmond, Virginia. Established in 1997, we have fully integrated Exelgen's world-leading computational molecular design and analysis software into our state of the art, purpose built high throughput chemistry facility. We offer successful, knowledge driven, drug discovery services which provide pharmaceutical and biotechnology companies innovative approaches to discover novel drug candidates efficiently. Applying proprietary computational design and therapeutic medicinal chemistry, Exelgen can reduce drug discovery timelines by up to 30%.

Additionally, we have applied our world class medicinal chemistry expertise to generate higher value and supplement our offerings by adopting an active in- and out-licensing strategy particularly directed at GPCR and kinase targets. The intention is to develop novel clinical candidates and ultimately proof-of-concept candidates for our partners with pre-emption rights agreed at the outset.

Since 1997, we have also been offering our successful LeadQuest® compound libraries. We have recently launched Volume 4, following on from the success of Volumes 0-3. We also offer LeadScreen™ screening libraries for rapid, economical screening, and LeadSelect™, a new approach to de novo compound libraries made to our customers' specifications.

To find out more, please visit our website, www.leadquest.com or contact .